Carmot Therapeutics was founded by Kian Chow in 2008. According to Bloomberg, Carmot Therapeutics announced its plans to go public in November 2023. However, in December 2023, Roche bought Carmot Therapeutics for $3.1 billion due to the high demand for obesity pharmaceuticals.
Carmot Therapeutics is a biotechnology company that helps people with metabolic diseases such as diabetes. Per Forge data, Carmot Therapeutics has raised a total of $384.8 million in 8 funding rounds. Their latest funding was raised on May 25, 2023, from a Series E round. Key investors include Amgen Ventures, Deep Track Capital, Horizen Ventures, and The Column Group.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/25/2023 | Series E | $150MM | $xx.xx | $69.67B | 5am Ventures, Deep Track Capital, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millenium Management, Ra Capital Management, Tcgx, The Column Group, Venrock Healthcare Capital Partners, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
6,519,392
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
5am Ventures, Deep Track Capital, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millenium Management, Ra Capital Management, Tcgx, The Column Group, Venrock Healthcare Capital Partners, Willett Advisors
|
||||||
08/26/2022 | Series D-1 | $30.23MM | $xx.xx | $46.49B | Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
1,853,391
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors
|
||||||
08/26/2022 | Series D | $130.44MM | $xx.xx | $46.49B | Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
6,798,176
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors
|
||||||
09/30/2020 | Series C | $46.88MM | $xx.xx | $17.97B | Amgen Ventures, Horizons Ventures, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
3,215,335
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Horizons Ventures, The Column Group
|
||||||
01/17/2018 | Series B | $12.59MM | $xx.xx | $5.74B | Horizons Ventures, Jerome Dahan, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
1,977,878
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Horizons Ventures, Jerome Dahan, The Column Group
|
||||||
04/07/2010 | Series A | $2.16MM | $xx.xx | $480.44MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,431,745
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|